Betaine supplementation protects against high-fructose-induced renal injury in rats

Fan, Chenyu; Wang, Mingxing; Ge, Chenxu; Wang, Xing; Li, Jianmei; Kong, Ling-Dong

doi:10.1016/j.jnutbio.2013.11.010

Cited by 85 publications

(62 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Di- etary fructose contributes to an increase in the input of energy, weight gain and alters blood lipid and carbohydrate homeostasis [22]. Insulin resistance and hyperinsulinemia are common in patients with metabolic syndrome, type II diabetes and essential hypertension, which are high risk factors of cardiovascular diseases, and play an important role in the development of coronary artery disease [5]. Our findings in the present study revealed that consumption of FDW (10% weight/ volume) during a month in rat model, induced gain of weight, insulin resistance index (IRI), hyperinsulinemia and hyperglycemia in these animals.…”

Section: Discussionmentioning

confidence: 99%

“…Research indicated that in fructose-fed rats (FFR) circulating triglyceride, the weight of liver, abdominal adipose tissue, and insulin resistance (IR) increased that was accompanied with impaired glucose tolerance [4]. Moreover, in FFR metabolic syndrome is induced which is correlated to hyperglycemia, dyslipidemia and insulin resistance [5][6][7]. Artemisia dracunculus (AD) is an herbal medicine whose extract has been shown to improve insulin sensitivity in vitro and in vivo studies [8].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of Artemisia dracunculus Aqueous Extract on Blood Sugar, Serum Insulin, Triglyceride and Liver Enzymes in Fructose Drinking Water Male Rats

Shahraki

Mirshekari

Saberi

et al. 2017

Zahedan J Res Med Sci

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effects of Artemisia dracunculus Aqueous Extract on Blood Sugar, Serum Insulin, Triglyceride and Liver Enzymes in Fructose Drinking Water Male Rats

Shahraki

Mirshekari

Saberi

et al. 2017

Zahedan J Res Med Sci

View full text Add to dashboard Cite

show abstract

“…3, we evaluated the levels of serum creatinine (S Cr ) and urine creatinine (U Cr ) in our experimental animals because there is a close correlation between creatinine and uric acid synthesis in gout patients [31][32][33]. As expected, the model group had a significantly higher S Cr level compared to that of the control group (P b 0.01).…”

Section: Effects Of Allopurinol Pallidifloside D and Their Combinatimentioning

confidence: 91%

Pallidifloside D from Smilax riparia enhanced allopurinol effects in hyperuricemia mice

Hou

et al. 2015

Fitoterapia

View full text Add to dashboard Cite

“…Fructose may contribute to liver and kidney injury through several mechanisms, including uric acid overproduction, and consistently, uric acid-lowering agents have improved fructose-induced experimental NAFLD and CKD (8,9) (Table 1). On this basis, the impact of xanthine oxidase inhibitors on CKD progression is being evaluated in the trials CKD-FIX ( Table 2).…”

Section: Potential Pathogenic Mechanisms Contributing To Nafld To Ckdmentioning

confidence: 99%

Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities

et al. 2016

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is a risk factor for end-stage renal disease (ESRD) and cardiovascular disease (CVD). ESRD or CVD develop in a substantial proportion of patients with CKD receiving standard-of-care therapy, and mortality in CKD remains unchanged. These data suggest that key pathogenetic mechanisms underlying CKD progression go unaffected by current treatments. Growing evidence suggests that nonalcoholic fatty liver disease (NAFLD) and CKD share common pathogenetic mechanisms and potential therapeutic targets. Common nutritional conditions predisposing to both NAFLD and CKD include excessive fructose intake and vitamin D deficiency. Modulation of nuclear transcription factors regulating key pathways of lipid metabolism, inflammation, and fibrosis, including peroxisome proliferatoractivated receptors and farnesoid X receptor, is advancing to stage III clinical development. The relevance of epigenetic regulation in the pathogenesis of NAFLD and CKD is also emerging, and modulation of microRNA21 is a promising therapeutic target. Although single antioxidant supplementation has yielded variable results, modulation of key effectors of redox regulation and molecular sensors of intracellular energy, nutrient, or oxygen status show promising preclinical results. Other emerging therapeutic approaches target key mediators of inflammation, such as chemokines; fibrogenesis, such as galectin-3; or gut dysfunction through gut microbiota manipulation and incretin-based therapies. Furthermore, NAFLD per se affects CKD through lipoprotein metabolism and hepatokine secretion, and conversely, targeting the renal tubule by sodium-glucose cotransporter 2 inhibitors can improve both CKD and NAFLD. Implications for the treatment of NAFLD and CKD are discussed in light of this new therapeutic armamentarium. EPIDEMIOLOGICAL EVIDENCE LINKING NAFLD AND CKDChronic kidney disease (CKD) affects up to 8% of the world's adult population, with its prevalence increasing in an aging population beset by lifestyle-associated diseases such as obesity, the metabolic syndrome, diabetes, hypertension, and smoking (1). CKD may progress to end-stage renal disease (ESRD) and is an important cardiovascular disease (CVD) risk factor. Importantly, most patients with CKD die as a result of CVD before renal replacement therapy is initiated (1).There is potential for improving recognition and treatment of CKD. In the Third National Health and Nutrition Survey, awareness among patients with stage 3 CKD was ,8% (1). Furthermore, ESRD or CVD develop in a substantial proportion of patients with CKD receiving standard-of-care therapy, and all-cause mortality remains unchanged in the CKD population (2). These data suggest that key pathogenetic mechanisms underlying

show abstract

Betaine supplementation protects against high-fructose-induced renal injury in rats

Cited by 85 publications

References 55 publications

Effects of Artemisia dracunculus Aqueous Extract on Blood Sugar, Serum Insulin, Triglyceride and Liver Enzymes in Fructose Drinking Water Male Rats

Effects of Artemisia dracunculus Aqueous Extract on Blood Sugar, Serum Insulin, Triglyceride and Liver Enzymes in Fructose Drinking Water Male Rats

Pallidifloside D from Smilax riparia enhanced allopurinol effects in hyperuricemia mice

Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities

Contact Info

Product

Resources

About